AstraZeneca: Saphnelo Demonstrates Higher Rates of Remission in Patients With Systemic Lupus Erythematosus Compared to Standard Therapy Alone Over 4-Year Period
March 22, 2024
March 22, 2024
WILMINGTON, Delaware, March 22 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on March 21, 2024:
* * *
AstraZeneca presents new post-hoc analysis from Phase III TULIP long-term extension trial at the European Lupus Meeting 2024
* * *
A new post-hoc analysis of the TULIP Phase III program provides evidence across four years that remission is an achievable goal with SAPHNELO(R) (anifrolumab-fnia), a first- . . .
* * *
AstraZeneca presents new post-hoc analysis from Phase III TULIP long-term extension trial at the European Lupus Meeting 2024
* * *
A new post-hoc analysis of the TULIP Phase III program provides evidence across four years that remission is an achievable goal with SAPHNELO(R) (anifrolumab-fnia), a first- . . .